Institution
Université Paris-Saclay
Education•Gif-sur-Yvette, France•
About: Université Paris-Saclay is a education organization based out in Gif-sur-Yvette, France. It is known for research contribution in the topics: Population & Context (language use). The organization has 29307 authors who have published 43183 publications receiving 867404 citations.
Topics: Population, Context (language use), Computer science, Medicine, Laser
Papers published on a yearly basis
Papers
More filters
TL;DR: The second part of the new evaluation of atomic masses, AME2020, is described in Part I as discussed by the authors using least-squares adjustments to all evaluated and accepted experimental data.
Abstract: This is the second part of the new evaluation of atomic masses, AME2020. Using least-squares adjustments to all evaluated and accepted experimental data, described in Part I, we derived tables with numerical values and graphs which supersede those given in AME2016. The first table presents the recommended atomic mass values and their uncertainties. It is followed by a table of the influences of data on primary nuclides, a table of various reaction and decay energies, and finally, a series of graphs of separation and decay energies. The last section of this paper provides all input data references that were used in the AME2020 and the NUBASE2020 evaluations.
1,248 citations
Duke University1, University of British Columbia2, Albert Einstein College of Medicine3, University of Parma4, University of Wisconsin-Madison5, Lenox Hill Hospital6, Columbia University7, New Generation University College8, Medical College of Wisconsin9, Stanford University10, University of Missouri11, National Institutes of Health12, University of California, Los Angeles13, Université Paris-Saclay14, University Hospital Heidelberg15, Sichuan University16, Cleveland Clinic17, Radboud University Nijmegen18, university of lille19, Catholic University of the Sacred Heart20, Osaka University21
TL;DR: A multidisciplinary panel comprised principally of radiologists and pulmonologists from 10 countries with experience managing COVID-19 patients across a spectrum of healthcare environments evaluated the utility of imaging within three scenarios representing varying risk factors, community conditions, and resource constraints, resulting in five main and three additional recommendations intended to guide medical practitioners in the use of CXR and CT in the management of COIDs.
1,232 citations
Université Paris-Saclay1, Netherlands Cancer Institute2, University of Siena3, University of Sydney4, University of Queensland5, Peter MacCallum Cancer Centre6, Alfred Hospital7, The Royal Marsden NHS Foundation Trust8, University of Western Australia9, Curie Institute10, University of Duisburg-Essen11, Radboud University Nijmegen Medical Centre12, Hannover Medical School13, Washington University in St. Louis14, Université de Montréal15, Merck & Co.16
TL;DR: As adjuvant therapy for high‐risk stage III melanoma, 200 mg of pembrolizumab administered every 3 weeks for up to 1 year resulted in significantly longer recurrence‐free survival than placebo, with no new toxic effects identified.
Abstract: Background The programmed death 1 (PD-1) inhibitor pembrolizumab has been found to prolong progression-free and overall survival among patients with advanced melanoma. We conducted a phase 3 double-blind trial to evaluate pembrolizumab as adjuvant therapy in patients with resected, high-risk stage III melanoma. Methods Patients with completely resected stage III melanoma were randomly assigned (with stratification according to cancer stage and geographic region) to receive 200 mg of pembrolizumab (514 patients) or placebo (505 patients) intravenously every 3 weeks for a total of 18 doses (approximately 1 year) or until disease recurrence or unacceptable toxic effects occurred. Recurrence-free survival in the overall intention-to-treat population and in the subgroup of patients with cancer that was positive for the PD-1 ligand (PD-L1) were the primary end points. Safety was also evaluated. Results At a median follow-up of 15 months, pembrolizumab was associated with significantly longer recurrence...
1,225 citations
Heidelberg University1, Korea Institute for Advanced Study2, University of Nottingham3, Institute of Cosmology and Gravitation, University of Portsmouth4, University of Oxford5, Istituto Nazionale di Fisica Nucleare6, University of Bologna7, INAF8, University of Padua9, University of Toulouse10, University of Geneva11, University of Trieste12, Roma Tre University13, University of Milan14, University of Oslo15, Federal University of Rio Grande do Norte16, University College London17, Imperial College London18, Ludwig Maximilian University of Munich19, Autonomous University of Madrid20, ETH Zurich21, University of Edinburgh22, Leiden University23, Sun Yat-sen University24, Max Planck Society25, Royal Institute of Technology26, University of Milano-Bicocca27, University of California, Berkeley28, University of Pennsylvania29, Universidade Federal do Espírito Santo30, University of Porto31, University of Portsmouth32, King's College London33, Durham University34, Institut d'Astrophysique de Paris35, Helsinki Institute of Physics36, University of Lisbon37, Paris Diderot University38, Université Paris-Saclay39, University of Surrey40, University of Trento41, University of Chile42, Academy of Sciences of the Czech Republic43, University of Cyprus44, University of Barcelona45, California Institute of Technology46, Perimeter Institute for Theoretical Physics47
TL;DR: Euclid is a European Space Agency medium-class mission selected for launch in 2020 within the cosmic vision 2015-2025 program as discussed by the authors, which will explore the expansion history of the universe and the evolution of cosmic structures by measuring shapes and red-shift of galaxies as well as the distribution of clusters of galaxies over a large fraction of the sky.
Abstract: Euclid is a European Space Agency medium-class mission selected for launch in 2020 within the cosmic vision 2015–2025 program. The main goal of Euclid is to understand the origin of the accelerated expansion of the universe. Euclid will explore the expansion history of the universe and the evolution of cosmic structures by measuring shapes and red-shifts of galaxies as well as the distribution of clusters of galaxies over a large fraction of the sky. Although the main driver for Euclid is the nature of dark energy, Euclid science covers a vast range of topics, from cosmology to galaxy evolution to planetary research. In this review we focus on cosmology and fundamental physics, with a strong emphasis on science beyond the current standard models. We discuss five broad topics: dark energy and modified gravity, dark matter, initial conditions, basic assumptions and questions of methodology in the data analysis. This review has been planned and carried out within Euclid’s Theory Working Group and is meant to provide a guide to the scientific themes that will underlie the activity of the group during the preparation of the Euclid mission.
1,211 citations
University of Michigan1, University of Utah2, Washington University in St. Louis3, University of Kiel4, University of Toronto5, Memorial University of Newfoundland6, Celera Corporation7, Emory University8, Université Paris-Saclay9, University of California, San Francisco10, Baylor University Medical Center11, Veterans Health Administration12
TL;DR: The results provide strong support for the association of at least seven genetic loci and psoriasis (each with combined P < 5 × 10−8) and suggest priority targets for study in other auto-immune disorders.
Abstract: Psoriasis is a common immune-mediated disorder that affects the skin, nails and joints. To identify psoriasis susceptibility loci, we genotyped 438,670 SNPs in 1,409 psoriasis cases and 1,436 controls of European ancestry. We followed up 21 promising SNPs in 5,048 psoriasis cases and 5,041 controls. Our results provide strong support for the association of at least seven genetic loci and psoriasis (each with combined P < 5 x 10(-8)). Loci with confirmed association include HLA-C, three genes involved in IL-23 signaling (IL23A, IL23R, IL12B), two genes that act downstream of TNF-alpha and regulate NF-kappaB signaling (TNIP1, TNFAIP3) and two genes involved in the modulation of Th2 immune responses (IL4, IL13). Although the proteins encoded in these loci are known to interact biologically, we found no evidence for epistasis between associated SNPs. Our results expand the catalog of genetic loci implicated in psoriasis susceptibility and suggest priority targets for study in other auto-immune disorders.
1,207 citations
Authors
Showing all 29679 results
| Name | H-index | Papers | Citations |
|---|---|---|---|
| Guido Kroemer | 236 | 1404 | 246571 |
| Patrick O. Brown | 183 | 755 | 200985 |
| Didier Raoult | 173 | 3267 | 153016 |
| Sophie Henrot-Versille | 171 | 957 | 157040 |
| Philippe Ciais | 149 | 965 | 114503 |
| Stanislas Dehaene | 149 | 456 | 86539 |
| Marc Humbert | 149 | 1184 | 100577 |
| Jean Bousquet | 145 | 1288 | 96769 |
| Jean-François Cardoso | 145 | 373 | 115144 |
| Marc Besancon | 143 | 1799 | 106869 |
| Maksym Titov | 139 | 1573 | 128335 |
| W. Kozanecki | 138 | 1498 | 99758 |
| Nabila Aghanim | 137 | 416 | 100914 |
| Yves Sirois | 137 | 1334 | 95714 |
| Patrick Janot | 136 | 1485 | 93626 |